Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2B P/E - EPS this Y -25.50% Ern Qtrly Grth -
Income -146.4M Forward P/E -11.57 EPS next Y -7.80% 50D Avg Chg -3.00%
Sales 38.02M PEG -0.74 EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 1.66 EPS next 5Y 10.00% 52W High Chg -54.00%
Recommedations 1.80 Quick Ratio 6.93 Shares Outstanding 292.78M 52W Low Chg 25.00%
Insider Own 28.09% ROA -9.79% Shares Float 191.76M Beta 0.38
Inst Own 43.87% ROE -12.27% Shares Shorted/Prior 23.04M/22.81M Price 6.94
Gross Margin 16.42% Profit Margin - Avg. Volume 3,156,685 Target Price 15.38
Oper. Margin -719.61% Earnings Date May 2 Volume 2,224,034 Change -4.54%
About AbCellera Biologics Inc.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, as well as strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc. News
03/26/24 Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks
03/19/24 AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
03/11/24 AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
03/05/24 AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
06:27 AM After losing 38% in the past year, AbCellera Biologics Inc. (NASDAQ:ABCL) institutional owners must be relieved by the recent gain
02/26/24 3 Highly Rated Biotech Stocks to Buy for 300% Gains
02/23/24 AbCellera Announces Resignation of Board Member
02/22/24 AbCellera to Present at Upcoming Investor Conferences in March
02/21/24 AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript
02/21/24 Q4 2023 Abcellera Biologics Inc Earnings Call
02/20/24 AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
02/20/24 AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
02/20/24 AbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic Shifts
02/20/24 AbCellera Reports Full Year 2023 Business Results
02/01/24 Techne (TECH) Q2 Earnings and Revenues Lag Estimates
01/30/24 Baillie Gifford Adjusts Stake in AbCellera Biologics Inc
01/23/24 AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
01/15/24 3 Growth Stocks That Could Go Parabolic in 2024
01/03/24 Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
12/20/23 AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
ABCL Chatroom

User Image tkstockpicker Posted - 1 day ago

$ABCL sold a little for about breakeven to manage risk. Size was just too big for me to be comfortable.

User Image hoggerj Posted - 1 day ago

$ABCL I'll be curious to see if they take this down by end of day.

User Image sogenerous Posted - 1 day ago

$ABCL $RXRX wish these 2 could merge - would be very diversified play then

User Image sogenerous Posted - 1 day ago

$ABCL nice response today - hard to overread into it tho

User Image CromieAds Posted - 1 day ago

$ABCL is my AI drug discovery stock for the next 10 years. $RXRX is good as well. Money will be chasing best of breed AI stocks in each category to diversify. I believe I found the best one.

User Image ks1111 Posted - 2 days ago

$ABCL I love buying cheap shit.

User Image ks1111 Posted - 2 days ago

$ABCL the stock market is so fuck8ng interesting. So much sentiment, so much trends, so much bullshit. This is proof that retail has a chance to outperform these so called professionals.

User Image ks1111 Posted - 2 days ago

$ABCL what idiots are selling this in this market.

User Image DeMampCamp Posted - 2 days ago

$ABCL working our way back to this gap fill…….smh!!

User Image aks_s Posted - 2 days ago

$ABCL Most pathetic stock in the history of stocks. I am looking for that freak confounded guy who wrote of piece of shit article in seeking alpha stating that it will be $500-$600 stock.

User Image Awald Posted - 2 days ago

$ABCL gap at 4.10$ area 👀🤫

User Image FreyBentos Posted - 2 days ago

$ABCL this thing will never bottom, just take it to $1 or wherever tf it needs to go for it not to keep bleeding day after day, week after week

User Image guggles Posted - 2 days ago

$ABCL fooo me

User Image sogenerous Posted - 2 days ago

Im perfectly comfortable if this goes to 1.7-2.7 . Remember you need this to go lower to have higher return because the upside for now is low $ABCL

User Image sogenerous Posted - 2 days ago

$ABCL amzing underperformer. I got 1000 share placeholder again 4.35. only 40-50 cents from bottom now. Ill see how it handles 3.8-4.0 and decide what to do. double bottom or hard break and 2s possibly 1s.

User Image Plutten1973 Posted - 2 days ago

$ABCL yes as I thought down to 4 ,I just wondering who's the winner? only stupid people sell at these leves so it must be shorters

User Image desiguy Posted - 2 days ago

$ABCL I can always lean on this to disappoint me lol

User Image Targhee Posted - 2 days ago

$ABCL only one stock in my list that is red so far today…can you guess which one?

User Image Plutten1973 Posted - 3 days ago

$ABCL hmmmm?! if u look at the three month graph it looks like the downtrend is here to stay , so maybe we reach low 4 or even 3,80 again... i hope its the bottom for the last time ,but im not sure for anything anymore but im sure i will never sell...

User Image sogenerous Posted - 3 days ago

$ABCL mgmt is so dumb here, all they needed to do was buy few $NVDA chips and say they are using NVDA BioNemo to assist in engineering next gen antibodies and stock would be $7-10. Absolute fools

User Image tranq19 Posted - 4 days ago

$ABCL $OABI Carl hasn’t bought lately, but my boy Foehr can’t get enough. I own both of these and go back and forth with momentum, but all in on OABI for now. Following his lead buying a cool $1.2M Friday, 3rd huge buy for him in the last year or so

User Image DeMampCamp Posted - 6 days ago

$ABCL Extremely low volume today, might be the lowest I've ever seen it, could be an indicator that most of the selling is dried up. Now, we just need a catalyst to get buyers interested. As others have mentioned, I believe we finally move up once rates are actually cut. Cheers and have a good weekend everyone!

User Image JaredSotken Posted - 1 week ago

$ABCL

User Image TickerDD_com Posted - 1 week ago

From 3/8/2024, looking back across 22 Month-Ends for ABCL, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had More Positives (95%) $ABCL #ABCL #ABCLStock #TickerDD https://www.youtube.com/watch?v=1znPekwADT8

User Image NotFinancialAdvise Posted - 1 week ago

$ABCL lol, this damn stock. Maybe it’ll be a winner 20 years from now when I’m getting ready to retire. Guess I’ll wait.

User Image FreyBentos Posted - 1 week ago

$ABCL all markets even IWM are hugely green but this thing manages to be in the rest somehow. Typical

User Image sogenerous Posted - 1 week ago

$ABCl 2022 revenue 485m , current TTM revenue 38m LOL . take this shit to 2s please where it belongs - insider options had strike of 2.7

User Image sogenerous Posted - 1 week ago

$ABCL even insiders stopped buying they have given up too, almost there another massive leg down then before its safe to swim again

User Image sogenerous Posted - 1 week ago

$ABCL the road to toilet cleaning - reload in 1-3s boys

User Image sogenerous Posted - 1 week ago

$ABCL break of 3.87 would be a knife thru the heart then drop it another $1 on top of that to 2s. I am interested there 1-2s please

Analyst Ratings
Benchmark Buy Feb 22, 24
Stifel Buy Feb 21, 24
Keybanc Overweight Dec 5, 23
Benchmark Buy Aug 31, 23
Goldman Sachs Buy Aug 4, 23
Credit Suisse Outperform May 5, 23
Cowen & Co. Outperform Feb 28, 23
BMO Capital Outperform Feb 22, 23
Credit Suisse Outperform Feb 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Montalbano John S. Director Director Nov 06 Buy 4.55 30,000 136,500 86,000 11/08/23
Hayden Michael R Director Director Sep 22 Buy 4.91 20,000 98,200 1,323,397 09/26/23
Lecault Veronique Chief Operating Offi.. Chief Operating Officer Sep 12 Buy 5.19 20,000 103,800 2,040,122 09/14/23
Hayden Michael R Director Director Aug 08 Buy 5.90 30,000 177,000 1,303,397 08/09/23
Booth Andrew Chief Financial Offi.. Chief Financial Officer Dec 20 Option 0.19 50,000 9,500 188,500 12/22/22
Thermopylae Holdings Ltd. 10% Owner 10% Owner Dec 16 Buy 10.0967 85,102 859,249 55,859,493 12/20/22
Hansen Carl L. G. Chief Executive Offi.. Chief Executive Officer Nov 18 Option 2.70 56,125 151,538 449,000 11/21/22
Thermopylae Holdings Ltd. 10% Owner 10% Owner Aug 19 Buy 11.4623 200,000 2,292,460 55,844,391 08/22/22
Hansen Carl L. G. Chief Executive Offi.. Chief Executive Officer Aug 18 Option 2.70 56,125 151,538 392,875 08/22/22
Thermopylae Holdings Ltd. 10% Owner 10% Owner Jun 13 Buy 8.04 64,088 515,268 55,644,391 06/15/22
Thermopylae Holdings Ltd. 10% Owner 10% Owner Jun 06 Buy 7.4981 64,545 483,965 55,580,303 06/08/22
Hansen Carl L. G. Chief Executive Offi.. Chief Executive Officer May 18 Option 2.70 56,125 151,538 336,750 05/19/22
Lecault Veronique Chief Operating Offi.. Chief Operating Officer May 16 Buy 6.3389 200,000 1,267,780 1,770,122 05/17/22
Thermopylae Holdings Ltd. 10% Owner 10% Owner May 13 Buy 7.2551 300,000 2,176,530 55,515,758 05/17/22
Montalbano John S. Director Director Mar 01 Buy 9.05 20,000 181,000 46,000 03/03/22
Lecault Veronique Chief Operating Offi.. Chief Operating Officer Feb 28 Buy 8.66 230,789 1,998,633 1,570,122 03/01/22
Hansen Carl L. G. Chief Executive Offi.. Chief Executive Officer Feb 22 Option 2.70 56,125 151,538 280,625 02/25/22
Booth Andrew Chief Financial Offi.. Chief Financial Officer Nov 11 Buy 14.68 67,500 990,900 130,959 11/15/21